Arrowhead Research | ARWR - Cash And Equivalent


Arrowhead Research reported $201.64M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Agios Pharmaceuticals USD 89.13M 3.58M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Anika Therapeutics USD 57.99M 4.82M Sep/2025
Arrowhead Research USD 201.64M 112.94M Dec/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Incyte USD 3.58B 650.78M Dec/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
Ligand Pharmaceuticals USD 664.52M 596.85M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Moderna USD 2.6B 1.46B Dec/2025
Nektar Therapeutics USD 41.03M 1.96M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
TG Therapeutics USD 178.32M 100.54M Sep/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025
Xencor USD 54.07M 25.78M Dec/2025